Heron Capital seeks to partner with experienced management teams in growth companies with the mutual goal of building long-term value.
The active management of the Heron portfolio companies is critical to our success. Consequently, we attend regular meetings with the management of each of the portfolio companies, developing a close working relationship with portfolio company management as a value-added advisor.
Our investment criteria centers on the following (click to expand):
+ DEDICATED MANAGEMENT AND EMPLOYEES
+ US HEADQUARTERS, PREFERABLY MIDWEST
+ GROSS MARGIN POTENTIAL OF 35% OR GREATER
+ EARNINGS UP TO $4M WITH UNREALIZED GROWTH POTENTIAL
AirXpanders Announces First Commercial U.S. Procedure for AeroForm® Tissue Expander System for Breast Reconstruction
January 18, 2017
US FDA grants de novo clearance to AirXpanders' AeroForm Tissue Expander System for breast reconstruction
December 26, 2016
First Patient Treated in U.S. Randomized Trial of NeoChord’s, Off-Pump, Minimally Invasive Repair for Degenerative Mitral Regurgitation
November 9, 2016